psilocybin – Page 7

Investigating the Potential of Psilocybin for Compulsive Eating in a Rat Model of Binge Eating

mycolabadmin

Researchers tested whether psilocybin, a psychedelic compound from magic mushrooms, could help reduce compulsive eating in rats bred to binge eat high-fat, high-sugar foods. Using a fear-conditioning experiment, they found that a single dose of psilocybin did not reduce the rats’ compulsive eating behavior at the dosage tested. However, the treatment may have affected fear-related freezing responses, suggesting psilocybin might influence brain circuits involved in learning and memory.

Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin

mycolabadmin

Researchers developed a new method to manufacture psilocybin, a promising therapeutic compound from magic mushrooms being tested to treat depression. Instead of using toxic chemicals, they replaced a difficult chemical step with an enzyme from the mushroom itself called PsiK. This approach produced gram amounts of pure psilocybin efficiently and could eventually lower costs for future medical use.

An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers

mycolabadmin

This study examined how a single high dose of psilocybin affects personality in healthy people. Participants who took psilocybin showed decreased anxiety-related personality traits (neuroticism) one month later. The effects were stronger in people who found the experience personally meaningful or who experienced more anxiety during the psychedelic state, suggesting that the intensity and meaning of the experience matters for lasting personality changes.

We need to talk about shrooms

mycolabadmin

The article discusses how psychedelic mushrooms have transformed from being seen as dangerous drugs in the 1960s to being studied as potential psychiatric treatments today. While research shows promise for treating depression, trauma, and addiction, the author warns against oversimplified narratives that ignore important context about how these experiences work and potential risks. The piece calls for careful, balanced discussion about psychedelics that considers both benefits and concerns.

Love (Drugs), Happiness, and Morality

mycolabadmin

This paper argues that love, happiness, and moral behavior create a self-reinforcing cycle: moral actions increase happiness, happiness promotes loving feelings, and love encourages more moral behavior. The author proposes that psilocybin and other love-enhancing drugs could strengthen this beneficial cycle, making them an ethical way for people to voluntarily improve themselves and society without requiring government mandates.

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

mycolabadmin

A 70-year-old man suffering from severe depression and anxiety caused by chronic Lyme disease and related tick-borne infections found relief after taking small doses of psilocybin mushrooms three times a week. Within days of starting treatment, his mood improved dramatically, and he remained symptom-free for two years. This case suggests that psilocybin’s ability to reduce inflammation in the brain may help patients with infectious-caused psychiatric conditions who cannot tolerate standard medications.

CORRECTION: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

mycolabadmin

A major research study examining psilocybin’s effectiveness for treating depression has been corrected due to mathematical and data handling errors. The researchers fixed these issues by recalculating statistics and removing duplicate data from their analysis. While the main conclusions remained similar after correction, the authors emphasize this research is still preliminary and should lead to further study before clinical use.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

mycolabadmin

This study directly compared two popular psychedelic drugs, LSD and psilocybin (magic mushrooms), in 28 healthy volunteers. Researchers found that these substances produce very similar mental effects when given at equivalent doses, with the main difference being that LSD lasts longer. The study establishes that about 20 milligrams of psilocybin is roughly equivalent to 100 micrograms of LSD. These findings could help guide dosing for future psychiatric treatments using these psychedelics.

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation

mycolabadmin

Researchers tested whether psilocybin, a compound from magic mushrooms, could protect pancreatic β-cells (which produce insulin) from damage caused by high glucose and fat levels. Using laboratory cells, they found that psilocybin reduced β-cell death by preventing apoptosis and showed promise in reducing dedifferentiation (when cells lose their specialized functions). However, psilocybin didn’t restore the cells’ ability to respond to glucose by releasing insulin.

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression

mycolabadmin

This research study is investigating how psilocybin, a compound from certain mushrooms, affects the brain in people with depression. The study involves 50 participants who will receive either psilocybin or a placebo, with their brain activity monitored using advanced imaging scans. Researchers will examine how psilocybin changes blood flow and network activity in brain regions involved in mood regulation, and whether these changes are linked to improvements in depression symptoms.

Research Keyword: psilocybin